z-logo
open-access-imgOpen Access
More Evolution of the Evidence in Asthma Disease Management-SMART Versus GOAL Clinical Trials Debate the Cost-Benefit of LABA While the Value of Leukotriene Modifiers, Particularly Montelukast, Is Uncertain
Author(s) -
Frederic R. Curtiss
Publication year - 2006
Publication title -
journal of managed care pharmacy
Language(s) - English
Resource type - Journals
eISSN - 1944-706X
pISSN - 1083-4087
DOI - 10.18553/jmcp.2006.12.4.343
Subject(s) - montelukast , medicine , asthma , leukotriene , value (mathematics) , intensive care medicine , clinical trial , machine learning , computer science

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom